Not time to RELAX in acute heart failure

The Lancet

Volumn 381, Issue 9880, 2013, Pages 1813-

  Ambrosy, Andrew P ^a   Witteles, Ronald M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SERELAXIN; RELAXIN;

ACUTE HEART FAILURE; DRUG MECHANISM; DYSPNEA; HUMAN; LETTER; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); FEMALE; HEART FAILURE; MALE; NOTE;

FEMALE; HEART FAILURE; HUMANS; MALE; RELAXIN;

EID: 84878031216     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)61116-2     Document Type: Letter

References (5)

1. Teerlink JR, Cotter G, Davison B.A., et al Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013; 381: 29-39.
2. Gheorghiade M, Ruschitzka F. Beyond dyspnoea as an endpoint in acute heart failure trials. Eur Heart J 2011; 32: 1442-45.
3. Collins SP, Pang PS, Lindsell C.J., et al International variations in the clinical, diagnostic, and treatment characteristics of emergency department patients with acute heart failure syndromes. Eur J Heart Fail 2010; 12: 1253-60.
4. Mebazaa A, Pang PS, Tavares M, et al The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. Eur Heart J 2010; 31: 832-41.
5. Blair JE, Khan S, Konstam M.A., et al Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial. Eur Heart J 2009; 30: 1666-73.